 |
| Capricor's stock price has soared since Monday. Chart from Google Finance |
On Dec. 29, Knoepfler predicted a “big
announcement from Big Pharma” in 2014. He did not have to wait
long to add some shine to his crystal ball.
On Monday, he wrote about the news that
Johnson&Johnson was pumping $12.5 million into Capricor
Therapeutics' stem cell therapy for heart disease. Capricor could see another $325 million from J&J if all goes well in
its stage two clinical trial, which is being supported by $20 million
from the California stem cell agency.
“I'd call that big money,”
Knoepfler wrote. He also noted in his blog he has no financial interest in either company.
Investors liked the news as well.
Capricor's stock closed at $7.05 today, more than double its $3.40
close on Friday, the business day just prior to J&J announcement.
No comments:
Post a Comment